Clinical Trials

Retinal Diagnostic Center is committed to giving our patients the most up-to-date medical care possible. Our participation in clinical trials affords our patients the opportunity to receive state-of-the art-treatment or medication, before these options are available commercially. We choose to participate only in clinical trials that may offer superior treatment, in comparison to currently available treatments, and clinical trials to treat conditions that currently have no approved treatment.

Our research department is headed by Amr Dessouki, M.D. who has been the principal investigator for several national and international multi-center clinical trials. He works closely with the American Institute of Research, the Diabetic Retinopathy Clinical Research Network, FDA and several pharmaceutical companies. Drs. Monahan, Chen and Chow participate as Co-investigators.

If one of our doctors believes you may benefit from being involved in a clinical trial, he will offer you the opportunity to meet with Dr. Dessouki or Dr. Chow and our research team. During this visit, you will undergo a detailed explanation of the trial and the consenting process. If you choose to participate, you will be scheduled for a screening visit, which involves an extensive eye examination and general medical history to determine if you are eligible for the study. Participation in these trials is completely voluntary and free. You will not be charged for any visit or treatment related to the trial.

Our research coordinator Tia Nguyen can be reached at (408) 559-0666, ext 119, Monday through Friday from 9:00 am to 5:00 pm. If you have any questions related to the trials please feel free to contact her.

Current clinical trials:

Study Name: SEQUOIA

Phase 3 - Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration

Study Sponsor: Allergan

Study Status: Currently enrolling patients

Study Name: Mako (Ohr-1601)

A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration

Study Sponsor: Ohr Pharmaceutical

Study Status: Currently Enrolling Patients

Study Name: Avenue (BP29647)

Phase 2, 36 weeks study comparing RO6867461 to Lucentis for Neovascular Age-related Macular Degeneration

Study Sponsor: Roche/Genentech

Study Status: Currently Enrolling Patients

Study Name: Proxima A (GX29633)

A multicenter, prospective epidemiologic study of the progression of geographic atrophy secondary to age-related macular degeneration.

Study Sponsor: Roche/Genentech

Study Status: Currently enrolling patients

Study Name: CIRCLE

Phase 2, Randomized, Double-masked, Sham Controlled, Multi-center study to Evaluate the Efficacy and Safety of Ocriplasmin (Jetrea) in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects with Non-Proliferative Diabetic Retinopathy. (NPDR)

Study Sponsor: Thrombogenic

Study Status: Currently Enrolling Patients

Study Name: OLE (GX29198)

A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with Geographic Atrophy who have completed Genentech sponsored Lampalizumab studies.

Study Sponsor: Roche/Genentech

Study Status: Currently Enrolling Patients

Study Name: Acacia (150998-007)

AbiCipar pegol safety and efficacy in Patients with Centrally-Involved Diabetic macular edema

Study Sponsor: Allergan

Study Status: Enrollment pending

Study Name: DRCR Protocol AB

Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy

Study Sponsor: Diabetic Retinopathy Clinical Research Network

Study Status: Enrollment pending

Study Name: Exposure (GX29455)

A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Adminstered Every Two Weeks or Every Four Weeks to Patients with Geographic Atrophy.

Study Sponsor: Roche/Genentech

Study Status: Closed

Study Name: Ophthotech Fovista

A phase 3 study comparing intravitreal Fovista (Anti PDGF-B Pegylated Aptamer) in combination with Lucentis vs. Lucentis alone in patients with wet macular degeneration.

Study Sponsor: Ophthotech Corporation

Study Status: Closed

Study Name: DRCR-Protocol V

A prospective study comparing 3 treatment options (Anti-VEGF injections vs. focal laser vs. observation) in patients with diabetic macular edema AND excellent vision (20/25 or better)

Study Sponsor: Diabetic Retinopathy Clinical Research Network

Study Status: Closed

Study Name: Ocriplasmin Research to Better Inform Treatment (ORBIT)

Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes

Study Sponsor: ThromboGenics

Study Status: Closed

Study Name: B1261009

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist (Oral Pill) With Ranibizumab In Adults With Diabetic Macular Edema

Study Sponsor: Pfizer

Study Status: Closed

Study Name: L-Path

A phase 2A study comparing a new medication called Sonepcizumab (iSONEPTM [LT1009]) to standard treatment (Eylea, Lucentis, or Avastin) in refractory exudative (wet) Age-Related Macular Degeneration

Study Sponsor: L-Path, Inc

Study Status: Complete

Study Name: HORIZON

A study to evaluate Ranizumab in subjects with choroidal neovascularization secondary to age-related macular degeneration or macular edema secondary to retinal vein occlusion.

Study Sponsor: Genentech

Study Status: Complete

Study Name: HARBOR

A study to test the efficacy and safety of Ranizumab administered monthly or on an as needed basis (PRN) in patients with subfoveal, neovascular age-related macular degeneration.

Study Status: Complete

Study Name: MIVI-TRUST

A trial of microplasmin intravitreal injection for non-surgical treatment of focal vtireomacular adhesion.

Study Sponsor: Thrombogenics

Study Status: Complete

Study Name: DRCR-Protocol S

Diabetic retinopathy clinical research network prompt pan retinal photocoagulation versus intravitreal ranizumab with deferred panretinal photocoagulation for proliferative diabetic retinopathy.

Study Sponsor: DRCR

Study Status: Complete

This is a list of past clinical trials that Retinal Diagnostic Center was a part of (you can find more detailed information on the web at clinicaltrials.gov):

Exudative (wet) Age-Related Macular Degeneration

Study Name: CABERNET

A study of locally applied radiation therapy for the treatment of exudative (wet) macular degeneration

Study Sponsor: Neovista

Study Status: Complete

Study Name: RADICAL

A study of combination therapy using photodynamic therapy, Lucentis(R) and Dexamethasone for the treatment of exudative (wet) macular degeneration.

Study Sponsor: QLT

Study Status: Complete

Study Name: VIEW1

A study of VEGF-trap injection for the treatment of exudative (wet) macular degeneration.

Study Sponsor: Regeneron

Study Status: Complete

Study Name: RISE

A study of Lucentis(R) injection for the treatment of diabetic macular edema.

Study Sponsor: Genentech

Study Status: Complete

Study Name: CRUISE

A study of Lucentis(R) injection for the treatment of macular edema due to central retinal vein occlusion.

Study Sponsor: Genentech

Study Status: Complete

Study Name: BRAVO

A study of Lucentis(R) injection for the treatment of macular edema due to branch retinal vein occlusion.

Study Sponsor: Genentech

Study Status: Complete


Schedule Online

Request your appointment by contacting one of our 7 locations

NEW!
  • We now accept all major Covered California ("Obamacare") plans (such as Blue Cross, Blue Shield, Health Net, etc). Please check with us to see if we are within your insurance network.
  • Click here to download the patient intake form. Fill these out and bring them to your appointment for faster check-in!

Recent posts
  • - RDC is proud to be part of the DRCR.net (NIH sponsored) Protocol S, which prompted the FDA to approve Genentech's Lucentis to treat all forms of diabetic retinopathy! Click here
  • - DRCR.net Protocol T: At 2 years, Eylea, Avastin, Lucentis all reduce need for injections, improve visual acuity
  • – RDC is proud to be part of the Diabetic Retinopathy Clinical Research Network. Read the latest New York Times article discussing NIH sponsored clinical trial results -- comparing Avastin, Lucentis and Eylea for diabetic macular edema